Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Herbert Hurwitz, MD
Study ID
NCT00276575
Phase
PHASE1
Status
Completed

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Erlotinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and everolimus may also block blood flow to the tumor. Giving everolimus and erlotinib together with bevacizumab may kill more tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of erlotinib and everolimus when given together with bevacizumab in treating patients with advanced solid tumors.

Key Dates

First listed
Jan 13, 2006
Start date
Mar 31, 2005
Status verified
Nov 2014
Primary completion
Oct 31, 2012
Completion
Sep 30, 2014

Study Design

Enrollment
65 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab, Everolimus, and Erlotinib
    Dose Level Dose Bevacizumab (mg/kg q2wks) Everolimus (mg daily) Erlotinib (mg daily) -1 5 5 --- 1. 10 5 --- 2. 10 10 --- 3. 10\* 10\* 75 4. 10\* 10\* 150

Primary Outcome Measure

Maximum Tolerated Dose [ Time Frame: Until study completion ]

Locations (1)

FacilityCityStateZIPSite coordinators
Duke Comprehensive Cancer CenterDurhamNorth Carolina27710-

Find similar trials in Durham, NC

By research site
Duke Comprehensive Cancer Center· Durham, NC

Related Studies